http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_770e8ccfe43da7085cd6644ed43c8c84
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Pusztai |
| name | Lajos Pusztai |
| given-name | Lajos |
| organization-name | Yale Cancer Center, Yale University, New Haven, Connecticut Authors' Affiliations: Departments of 1Breast Medical Oncology, 2Investigational Cancer Therapeutics, 3Bioinformatics/Quantitative Sciences, and 4Pathology of the University of Texas M.D. Anderson Cancer Center, Houston, Texas; 5Bristol-Myers Squibb Co., Princeton, New Jersey; 6University of Muenster, Muenster, Germany; and 7Nuvera Biosciences, Inc., Woburn, Massachusetts Authors' Affiliations: 1Center for Functional Cancer Epigenetics, 2Department of Medical Oncology, Dana-Farber Cancer Institute; 3Department of Medicine, Brigham and Women's Hospital; Departments of 4Pathology and 5Breast Medical Oncology Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; 6Foundation Medicine, Cambridge, Massachusetts; 7Departments of Investigational Cancer Therapeutics, Surgical Oncology, and 8Systems Biology and Breast Medical Oncology, The University of MD Anderson Cancer Center, Houston, Texas; 9Fundacion de Investigacion INCLIVA-Institute for Health Research; 10Departments of Hematology-Oncology, Hospital Clinico Universitario de Valencia, Valencia, Spain; 11Jefferson Breast Care Center, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania; 12Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Perú; 13Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; 14Teva Pha From the University of Wisconsin Carbone Cancer Center, Madison, WI; Department of Medicine, Division of Hematology/Oncology, University of Wisconsin, Madison, WI; Yale Cancer Center, New Haven, CT; Princess Margaret Hospital, Calgary, ON, Canada; Princess Margaret Cancer Center, Toronto, ON, Canada. Yale Cancer Center, New Haven, CT From the Department of Breast Medical Oncology and the Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Breast Cancer Unit, Department of Medical Oncology and Translational Research Unit, UPRES EA03535, Université Paris Sud, Institut Gustave Roussy, Villejuif; Department of Medical Oncology, Institut Claudius Regault, Toulouse; Department of Pathology, Center Claude Perrin, Clermont-Ferrand, France; Department of Oncology, Hospital Universitario San... 3Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas Departments of 1Molecular Pathology, 2Pathology, 3Biostatistics, 4Surgical Oncology, and 5Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas From the Johns Hopkins Sydney Kimmel Cancer Center, Baltimore; National Cancer Institute, Bethesda, MD; The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of North Carolina, Chapel Hill, NC; European Institute of Oncology, Milan, Italy; Royal Marsden Hospital, London, United Kingdom; Washington University School of Medicine, St Louis, MO; Dana-Farber Cancer Institute, Boston, MA; University of Washington School of Medicine, Seattle, WA; Division of Pathology, National Surgical... Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA 1Breast Medical Oncology and Departments of Department of Medical Oncology, Yale School of Medicine, New Haven, CT Department of Breast Medical Oncology, Unit 424, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA. lpusztai@ mdanderson.org Department of Breast Medical Oncology Takayuki Iwamoto, Daniel Booser, Vicente Valero, James L. Murray, Kimberly Koenig, Francisco J. Esteva, Naoto T. Ueno, Jie Zhang, Weiwei Shi, Yuan Qi, Elliana J. Yang, Gabriel N. Hortobagyi, W. Fraser Symmans, and Lajos Pusztai, The University of Texas MD Anderson Cancer Center, Houston, TX; Takayuki Iwamoto and Junji Matsuoka, Okayama University, Okayama, Japan; and Christos Hatzis, Nuvera Biosciences, Woburn, MA. Departments of Medicine and Pathology, M.D. Anderson Cancer Center, Houston, Texas, USA a Departments of Breast Medical Oncology, Houston, Texas, USA 1Breast Medical Oncology, Departments of From the Departments of Breast Medical Oncology, Pathology, and Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX Yale Cancer Center Genomics Program, Yale Cancer Center, Yale School of Medicine New Haven CT USA Yale Cancer Center Genetics and Genomics Program, Yale School of Medicine, New Haven, CT, U.S.A. From the Yale University School of Medicine. 1Department of Internal Medicine, Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut. W. Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Maheshwari Ramineni, Kelly Hunt, Thomas A. Buchholz, Vicente Valero, Aman U. Buzdar, Wei Yang, Abenaa M. Brewster, Stacy Moulder, and Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston; Andrew Walls, Uniformed Services University of the Health Sciences, San Antonio, TX; Mei Liu, The General Hospital of People’s Liberation Army, Beijing, China; Alex Bousamra, Allegheny General Hospital, Pittsburgh, PA; Bruno Sinn,... From the Departments of Surgical Oncology, Breast Medical Oncology, Systems Biology, Biostatistics, and Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Authors' Affiliations: 1Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2Department of Gastroenterological Surgery and Surgical Oncology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan; Departments of 3Bioinformatics, 4Breast Medical Oncology, and 5Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 6Department of Gynecology and Obstetrics, University Pierre et Marie Curie Tenon Hospital, Paris, France; and 7Translational Research Unit, Department of Medical Oncology, Hospital of Prato and Istituto Toscana Tumori, Prato, Italy Department of Medicine Yale Comprehensive Cancer Center, Yale University School of Medicine New Haven Connecticut From the Departments of Breast Medical Oncology, Biostatistics and Applied Mathematics, and Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, University of Münster, Münster, Germany; Department of Obstetrics and Gynecology, Marseille Public Hospital System, Marseille; and Breast Cancer Unit and Translational Research Unit UPRES03535, Institut Gustave Roussy, Villejuif, France Department of Breast Medical Oncology, The University of Texas M.D. Authors' Affiliations: 1Department of Breast Medical Oncology, 2Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Departments of 3Molecular and Cellular Oncology, 4Pathology, 5Radiation Oncology, and 6Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 7Tolero Pharmaceuticals, Inc., Salt Lake City, Utah; and 8Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan From the Departments of Breast Medical Oncology and Radiation Oncology Treatment, The University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Obstetrics and Gynecology, Institut Mère Enfant Alix de Champagne, Centre Hospitalier Universitaire, Reims; Departments of Obstetrics and Gynecology and Radiation Oncology, Hôpital Tenon, Assistance Publique Hôpitaux de Paris, University Pierre et Marie Curie, Paris 6 and UPRES EA 4053, Paris, France; Department of Radiation Oncology, Cross... From the Departments of Pathology, Surgery, and Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX; and Nuvera Biosciences Inc, Woburn, MA 1Breast Medical Oncology, Departments of; 4Breast Cancer Translational Research Laboratory, and Breast Medical Oncology, Yale School of Medicine, New Haven, CT, USA. From The University of Texas M. D. Anderson Cancer Center, Houston, TX; Nuvera Biosciences, Woburn, MA; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan; University Pierre et Marie Curie Tenon Hospital, Paris; and Institut Gustave-Roussy, Villejuif, France. Yale University School of Medicine; Yale New Haven Hospital–Smilow Cancer Hospital, New Haven, CT Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030; Departments of Breast Medical Oncology, Pathology, Biostatistics and Applied Mathematics, Radiation Oncology, and Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; Millennium Pharmaceuticals, Cambridge, MA 02139; Albany Medical College, Albany, NY 12208; and Department of Gynecological Oncology, Institut Gustave-Roussy, 94805 Villejuif, France Yale Cancer Center, Yale School of Medicine, Breast Medical Oncology, New Haven, USA. lajos.pusztai@yale.edu. 2Yale Cancer Center Genetics and Genomics Program, Yale University School of Medicine, New Haven, Connecticut. 7Genetics and Genomics Program, Yale School of Medicine, New Haven, Connecticut. The University of Texas M.D. Anderson Cancer Center, Division of Breast Medical Oncology, Houston, TX, USA Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA From The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; M.D. Anderson Cancer Center, Houston, TX 77230; and Agendia BV, 1098 SM Amsterdam, the Netherlands. Medical Oncology, Yale Cancer Center, Yale School of Medicine, CT 06520, New Haven, USA Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut Yale Cancer Center, New Haven, Connecticut, USA; University of Texas, MD Anderson Cancer Center, Department of Breast Medical Oncology, Unit 1354, PO Box 301439, Houston, TX 77230–1439, USA. Yale School of Medicine, New Haven, Connecticut, USA From the Istituto Nazionale Tumori, Milan, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX: Genomic Health Inc, Redwood City, CA; and Millennium Pharmaceuticals Inc, Cambridge, MA Yale University, New Haven, Connecticut Peter Gershkovich, Joshua Knopf, Lajos Pusztai, Christos Hatzis, Yale School of Medicine, New Haven; James Platt, Biomantica, West Haven, CT; Marios K. Tasoulis, The Royal Marsden National Health Services Foundation Trust, London, United Kingdom; and Weiwei Shi, Origimed, Shanghai, China. From the Departments of Breast Medical Oncology, Department of Biostatistics, and the Division of Medicine and Pathology of the University of Texas M.D. Anderson Cancer Center, Houston TX; and Cell Pathways Inc, Horsham, PA. Departments of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-009, USA. lpusztai@mdanderson.org Authors' Affiliations: Departments of 1Breast Medical Oncology, 2Biostatistics, 3Pathology, 4Systems Biology, and 5Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 6Division of Hematology-Oncology, Yale University, New Haven, Connecticut From The Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; M.D. Anderson Community Clinical Oncology Program, Decatur, IL. From the Departments of Breast Medical Oncology, Pathology, and Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, University Muenster, Muenster, Germany; Nuvera Biosciences, Woburn, MA; Translational Research Unit, Jules Bordet Institute, Brussels, Belgium; Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium. Authors' Affiliations: Departments of 1Breast Medical Oncology, 2Bioinformatics and Computational Biology, and 3Pathology, The University of Texas M.D. Anderson Cancer Center; 4Lyndon B Johnson General Hospital, and The University of Texas Health Science Center, Houston, Texas; 5Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; 6Grupo Español de Investigacion en Cancer de Mama, Madrid, Spain; and 7Centro Medico Nacional de Occidente, Guadalajara, Mexico Authors' Affiliations: Departments of 1Breast Medical Oncology, 2Bioinformatics and Computational Biology, and 3Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 4Department of Obstetrics and Gynecology, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, University Pierre et Marie curie-Paris, UPRES EA 4053, Paris, France; 5Division of Biostatistics and Epidemiology, and Departments of 6Urology and 7Public Health Sciences, University of Virginia, Charlottesville, Virginia From the Institut Jules Bordet; Machine Learning Group, Université Libre de Bruxelles; Hôpitaux Iris Sud–Site Etterbeek-Ixelles; Hopital Saint-Pierre, Brussels; Clinique Saint-Pierre, Ottignies; Clinique Ste Elisabeth, Namur; International Drug Development Institute, Louvain-La-Neuve, Belgium; Hospital of Prato, Prato, Italy; Institut Gustave Roussy, Villejuif, France; Centre Hospitalier du Luxembourg, Luxembourg, Luxembourg; and University of Texas MD Anderson Cancer Center, Houston, TX. Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut University of Rochester Breast Medical Oncology Section, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut From the Departments of Breast Medical Oncology, Biostatistics and Applied Mathematics, and Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Breast Cancer Unit and UPRES EA, Institut Gustave Roussy, Villejuif, France; and Departments of Gynecologic Oncology and Breast Cancer Surgery (DA), Hotel-Dieu, Beirut, Lebanon. Yale Cancer Center, Yale School of Medicine, New Haven, CT From The University of Texas M. D. Anderson Cancer Center, Houston TX; Nuvera Biosciences, Woburn, MA; Institut Jules Bordet, Brussels, Belgium; Institut Gustave Roussy, Villejuif, France; General Hospital Leoben, Loeben; Medical University of Graz, Graz; and Medical University of Innsbruck, Austria. Authors' Affiliation: Departments of Breast Medical Oncology, Biostatistics and Applied Math, Surgical Oncology, Pathology, Cardiology, and Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Hannah Dzimitrowicz, Annette Hood, Osama Abdelghany, Christos Hatzis, and Lajos Pusztai, Yale University School of Medicine, New Haven, CT; Michael Berger and Craig Vargo, The James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH; and Akshara Singareeka Raghavendra, Debu Tripathy, Vicente Valero, and Rashmi Murthy, MD Anderson Cancer Center, Houston, TX. g MD Anderson Cancer Center, Houston, Texas, USA From the Departments of Breast Medical Oncology and Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; National Surgical Adjuvant Breast and Bowel Project Biostatistical Center; the Departments of Biostatistics and Pathology, University of Pittsburgh, Pittsburgh, PA; the Department of Pathology, Albany Medical College, Albany, NY; Department of Gynecologic Oncology Hopital Tenon, Paris; and the Translational Research Unit, Institute Gustave Roussy, Villejuif, France. 8Yale Cancer Center, Breast Medical Oncology, New Haven, Connecticut. Department of Medical Oncology, Yale School of Medicine, Yale University, New Haven, Connecticut Department of Medicine, Yale Cancer Center, Yale University, New Haven, CT Yale School of Medicine, New Haven, CT Yale Cancer Center Yale University New Haven CT USA; Department of Medical Oncology, Yale School of Medicine Yale University New Haven CT USA 3Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut. From the Departments of Biostatistics and Applied Mathematics, Pathology, Breast Medical Oncology and Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Breast Cancer Unit and Unité Propre de l'Enseignement Supérieur; Equipe d'Accueil 3535 of the Institut Gustave Roussy, Villejuif, France; Albany Medical College, Albany NY; Departamento de Medicina Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut. b Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; From the Departments of Breast Medical Oncology, Ophthalmology, Laboratory Medicine, Pathology, and Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX. The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Yale School of Medicine, New Haven, Connecticut. Yale Cancer Center, New Haven, Connecticut, USA From the Departments of Breast Medical Oncology, Biostatistics, Surgical Oncology, Pathology, Cardiology, and Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX Yale Cancer Center, School of Medicine, Yale University, New Haven, Connecticut, USA Systems Biology, and Authors' Affiliations: Departments of 1Pathology and 2Medical Oncology, Yale School of Medicine, New Haven, Connecticut; and 3Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio Authors' Affiliations: 1University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; 2The University of Texas MD Anderson Cancer Center, Houston, Texas; 3National Cancer Institute, Bethesda, Maryland; 4University of California, San Francisco, San Francisco; 5University of California San Diego, San Diego; and 6University of Southern California, Los Angeles, California; 7Stritch School of Medicine, Loyola University Chicago, Maywood; and 8University of Chicago Medical Center, Chicago, Illinois; 9Mayo Clinic, Rochester; and 10University of Minnesota, Minneapolis, Minnesota; 11Sanford Health System, Sioux Falls, South Dakota; and 12Yale School of Medicine, New Haven, Connecticut Department of Internal Medicine Section of Medical Oncology and Yale Cancer Center, School of Medicine, Yale University, New Haven, Connecticut. Yale Cancer Center Yale School of Medicine New Haven Connecticut USA 4Yale School of Medicine, Medical Oncology, New Haven, Connecticut. Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA;... Yale University School of Medicine, New Haven, Connecticut, USA; Yale School of Medicine, New Haven, Connecticut d Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Tara Sanft and Lajos Pusztai, Yale University School of Medicine, New Haven, CT Yale University School of Medicine Yale Comprehensive Cancer Center, Yale School of Medicine , 333 Cedar Street, New Haven, Connecticut, 06520 , U.S.A. Yale University School of Medicine, New Haven, Connecticut, USA Authors' Affiliations: Departments of 1Breast Medical Oncology, 2Bioinformatics, and 3Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 4Department of Gynecology and Obstetrics, University Pierre et Marie Curie, Paris 6 and UPRES EA 4053, Tenon Hospital, Assistance Publique des Hôpitaux de Paris; 5Department of Biochemistry and INSERM U944 University Rene Diderot, Paris 7, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; 6Division of Medical Oncology, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy; 7Department of Gastroenterological Surgery and Surgical Oncology, Okayama, University Graduate School of Medicine and Dentistry, Okayama, Japan; and 8The Translational Research Unit, Institut Gustave Roussy, Villejuif, France Authors' Affiliations: Departments of 1Breast Medical Oncology, 2Systems Biology, 3Biostatistics, 4Surgical Oncology, and 5Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas From The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Brown University, Providence, RI Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA 1Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, Yale University, New Haven, Connecticut.; 2Yale Cancer Center, New Haven, Connecticut. 1Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut. Authors' Affiliations: 1Bristol-Myers Squibb, Princeton, New Jersey; 2Yale Cancer Center, New Haven; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; 5National Yang-Ming University, Taipei-Veterans General Hospital, Taipei, Taiwan; 6Nottingham University Hospital, Nottingham, United Kingdom; and 7Dako North America, Inc., Carpinteria, California 8Breast Medical Oncology and MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX 77030-4009, USA. lpusztai@mdanderson.org Yale University School of Public Health; and Yale University School of Medicine, New Haven, CT The University of Texas MD Anderson Cancer Center, Houston, TX Rita Nanda, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; E. Claire Dees, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Raanan Berger, Sheba Medical Center, Tel Hashomer; Ravit Geva, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Lajos Pusztai, Yale University School of Medicine, New Haven, CT; Kumudu Pathiraja, Gursel Aktan, Jonathan D.... Yale University School of Medicine; and Yale Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT All authors: The University of Texas MD Anderson Cancer Center, Houston, TX. M.D. Anderson Cancer Center, University of Texas, Houston, Houston, TX Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 424, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. lpusztai@mdanderson.org Yale School of Medicine; and Yale School of Nursing, New Haven, CT Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230–1439, USA. Breast Medical Oncology, Yale School of Medicine, New Haven, CT, USA 2Breast Medical Oncology, 1Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut. University of Texas, Breast Medical Oncology, 1515 Holcombe Blvd, Houston, TX 77030, USA Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA From the Departments of Breast Medical Oncology and Pathology and Division of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and the Translational Research Unit, Institut Gustave Roussy, Villejuif, France Medical Oncology, Yale Cancer Center, New Haven, Connecticut Yale School of Medicine, Yale University, New Haven, CT 06510, USA. Brigid K. Killelea, Brandon Hayse, Sarah Mougalian, Nina R. Horowitz, Anees B. Chagpar, Lajos Pusztai, and Donald R. Lannin, Yale University School of Medicine; Brigid K. Killelea, Sarah Mougalian, Nina R. Horowitz, Anees B. Chagpar, Lajos Pusztai, and Donald R. Lannin, Yale Comprehensive Cancer Center; and Vicky Q. Yang and Shi-Yi Wang, Yale University School of Public Health, New Haven, CT. From the Winship Cancer Institute at Emory University, Atlanta (K.K.); Southwest Oncology Group Statistics and Data Management Center (W.E.B., D.L.L., J.M.) and the University of Washington School of Medicine–Seattle Cancer Care Alliance (J.R.G.) — both in Seattle; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.T., G.N.H.); Loyola University Chicago, Maywood, IL (K.S.A.); the University of Michigan, Ann Arbor (D.F.H., A.F.S.); Dana–Farber Cancer Institute, Boston (N.U.L.); Mayo... a Department of Breast Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA Author's Affiliation: Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 4Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas and 1Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut. b Departments of Pathology, Breast Medical Oncology, and Biostatistics and Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut Department of Medicine, Medical Oncology, Yale University, New Haven, Connecticut Section of Medical Oncology, Yale Cancer Center Yale School of Medicine New Haven Connecticut Yale Cancer Center New Haven CT USA; Department of Medical Oncology Yale School of Medicine New Haven CT USA |
Incoming Links
Total number of triples: 527.